CoChat
Sign Up
Cited by 376Cytokine Signaling Pathways and InteractionsImmune cells in cancerIL-33, ST2, and ILC Pathways

IL‐1 and IL‐1 regulatory pathways in cancer progression and therapy

Open access
Mantovani, Alberto, Barajon, Isabella, Garlanda, Cecilia·2018·Immunological Reviews
DOI 10.1111/imr.12614PMC PMC5922413
Open this paper in CoChat — free account

Abstract

Summary: Inflammation is an important component of the tumor microenvironment. IL‐1 is an inflammatory cytokine which plays a key role in carcinogenesis and tumor progression. IL‐1 is subject to regulation by components of the IL‐1 and IL‐1 receptor (ILR) families. Negative regulators include a decoy receptor (IL‐1R2), receptor antagonists (IL‐1Ra), IL‐1R8, and anti‐inflammatory IL‐37. IL‐1 acts at different levels in tumor initiation and progression, including driving chronic non‐resolving inflammation, tumor angiogenesis, activation of the IL‐17 pathway, induction of myeloid‐derived suppressor cells (MDSC) and macrophage recruitment, invasion and metastasis. Based on initial clinical results, the translation potential of IL‐1 targeting deserves extensive analysis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/imr.12614

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Management of acute and chronic inflammatory conditions including infections may modify risk for clonal expansion and subsequent malignancy.

    “thus supporting the concept that management of acute and chronic inflammatory conditions including infections may modify risk for clonal expansion and subsequent malignancy (Binder et al., 2018; Mantovani et al., 2018).”

    From Chronic infection drives Dnmt3a-loss-of-function clonal hematopoiesis via IFNγ signaling (2021) · cites this paper as Mantovani et al., 2018

    The Introduction links chronic inflammatory conditions, including infection, to increased cancer risk. The Concluding remarks say IL-1 targeting may affect cancer incidence, supporting the possibility that managing inflammation could modify malignancy risk. The paper does not extend that conclusion to management of acute infections or describe a resulting change in clonal expansion. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 45

  1. [1]Mantovani A Allavena P Sica A Balkwill F Cancer-related inflammation Nature 2008 454 436 444 18650914
  2. [2]Biswas SK Mantovani A Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm Nat Immunol 2010 11 889 896 20856220
  3. [3]Mantovani A Marchesi F Malesci A Laghi L Allavena P Tumour-associated macrophages as treatment targets in oncology Nat Rev Clin Oncol 2017 14 399 416 28117416 PMC5480600
  4. [4]Coussens LM Zitvogel L Palucka AK Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 2013 339 286 291 23329041 PMC3591506
  5. [7]Netea MG Balkwill F Chonchol M A guiding map for inflammation Nat Immunol 2017 18 826 831 28722720 PMC5939996
  6. [8]Dinarello CA Simon A van der Meer JW Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases Nat Rev Drug Discov 2012 11 633 652 22850787 PMC3644509
  7. [10]Colotta F Re F Muzio M Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4 Science 1993 261 472 475 8332913
  8. [11]Li S Neff CP Barber K Extracellular forms of IL-37 inhibit innate inflammation in vitro and in vivo but require the IL-1 family decoy receptor IL-1R8 Proc Natl Acad Sci U S A 2015 112 2497 2502 25654981 PMC4345608
  9. [12]Nold-Petry CA Lo CY Rudloff I IL-37 requires the receptors IL-18Ralpha and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction Nat Immunol 2015 16 354 365 25729923
  10. [13]Molgora M Barajon I Mantovani A Garlanda C Regulatory Role of IL-1R8 in Immunity and Disease Front Immunol 2016 7 149 27148268 PMC4837151
  11. [14]Molgora M Bonavita E Ponzetta A IL-1R8 is a checkpoint in NK cells regulating anti-tumour and anti-viral activity Nature 2017 551 110 114 29072292 PMC5768243
  12. [15]Cataisson C Salcedo R Hakim S IL-1R-MyD88 signaling in keratinocyte transformation and carcinogenesis J Exp Med 2012 209 1689 1702 22908325 PMC3428947
  13. [16]Apte RN Dotan S Elkabets M The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions Cancer Metastasis Rev 2006 25 387 408 17043764
  14. [17]Voronov E Shouval DS Krelin Y IL-1 is required for tumor invasiveness and angiogenesis Proc Natl Acad Sci U S A 2003 100 2645 2650 12598651 PMC151394
  15. [18]Krelin Y Voronov E Dotan S Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors Cancer Res 2007 67 1062 1071 17283139
  16. [19]Elkabets M Krelin Y Dotan S Host-derived interleukin-1alpha is important in determining the immunogenicity of 3-methylcholantrene tumor cells J Immunol 2009 182 4874 4881 19342666
  17. [20]Murphy JE Morales RE Scott J Kupper TS IL-1 alpha, innate immunity, and skin carcinogenesis: the effect of constitutive expression of IL-1 alpha in epidermis on chemical carcinogenesis J Immunol 2003 170 5697 5703 12759452
  18. [21]El-Omar EM Carrington M Chow WH Interleukin-1 polymorphisms associated with increased risk of gastric cancer Nature 2000 404 398 402 10746728
  19. [22]Salcedo R Cataisson C Hasan U Yuspa SH Trinchieri G MyD88 and its divergent toll in carcinogenesis Trends Immunol 2013 34 379 389 23660392 PMC3847901
  20. [23]Giavazzi R Garofalo A Bani MR Interleukin 1-induced augmentation of experimental metastases from a human melanoma in nude mice Cancer Res 1990 50 4771 4775 2196116
  21. [24]Vidal-Vanaclocha F Amezaga C Asumendi A Kaplanski G Dinarello CA Interleukin-1 receptor blockade reduces the number and size of murine B16 melanoma hepatic metastases Cancer Res 1994 54 2667 2672 8168095
  22. [25]Vidal-Vanaclocha F Alvarez A Asumendi A Urcelay B Tonino P Dinarello CA Interleukin 1 (IL-1)-dependent melanoma hepatic metastasis in vivo; increased endothelial adherence by IL-1-induced mannose receptors and growth factor production in vitro J Natl Cancer Inst 1996 88 198 205 8632494
  23. [26]Vidal-Vanaclocha F Fantuzzi G Mendoza L IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1 Proc Natl Acad Sci U S A 2000 97 734 739 10639148 PMC15399
  24. [27]McKenzie RC Oran A Dinarello CA Sauder DN Interleukin-1 receptor antagonist inhibits subcutaneous B16 melanoma growth in vivo Anticancer Res 1996 16 437 441 8615650
  25. [28]Chirivi RG Garofalo A Padura IM Mantovani A Giavazzi R Interleukin 1 receptor antagonist inhibits the augmentation of metastasis induced by interleukin 1 or lipopolysaccharide in a human melanoma/nude mouse system Cancer Res 1993 53 5051 5054 8267795
  26. [29]Carmi Y Voronov E Dotan S The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis J Immunol 2009 183 4705 4714 19752225
  27. [30]Voronov E Carmi Y Apte RN The role IL-1 in tumor-mediated angiogenesis Front Physiol 2014 5 114 24734023 PMC3975103
  28. [31]Mantovani A Bussolino F Dejana E Cytokine regulation of endothelial cell function FASEB J 1992 6 2591 2599 1592209
  29. [33]Roy S Trinchieri G Microbiota: a key orchestrator of cancer therapy Nat Rev Cancer 2017 17 271 285 28303904
  30. [34]Thomas S Izard J Walsh E The Host Microbiome Regulates and Maintains Human Health: A Primer and Perspective for Non-Microbiologists Cancer Res 2017 77 1783 1812 28292977 PMC5392374
  31. [35]Garlanda C Riva F Veliz T Increased susceptibility to colitis-associated cancer of mice lacking TIR8, an inhibitory member of the interleukin-1 receptor family Cancer Res 2007 67 6017 6021 17616656
  32. [36]Xiao H Gulen MF Qin J The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis Immunity 2007 26 461 475 17398123
  33. [37]Wang K Kim MK Di Caro G Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis Immunity 2014 41 1052 1063 25526314 PMC4272447
  34. [38]Galdiero MR Bianchi P Grizzi F Occurrence and significance of tumor-associated neutrophils in patients with colorectal cancer Int J Cancer 2016 139 446 456 26939802
  35. [39]Pan W Zhu S Qu K The DNA Methylcytosine Dioxygenase Tet2 Sustains Immunosuppressive Function of Tumor-Infiltrating Myeloid Cells to Promote Melanoma Progression Immunity 2017 47 284 297 e285 28813659 PMC5710009
  36. [41]Elkabets M Ribeiro VS Dinarello CA IL-1beta regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function Eur J Immunol 2010 40 3347 3357 21110318 PMC3373225
  37. [43]Mantovani A The growing diversity and spectrum of action of myeloid-derived suppressor cells Eur J Immunol 2010 40 3317 3320 21110315
  38. [44]Bhat IA Naykoo NA Qasim I Association of interleukin 1 beta (IL-1beta) polymorphism with mRNA expression and risk of non small cell lung cancer Meta Gene 2014 2 123 133 25606396 PMC4287803
  39. [45]Lind H Zienolddiny S Ryberg D Skaug V Phillips DH Haugen A Interleukin 1 receptor antagonist gene polymorphism and risk of lung cancer: a possible interaction with polymorphisms in the interleukin 1 beta gene Lung Cancer 2005 50 285 290 16126303
  40. [46]Zienolddiny S Ryberg D Maggini V Skaug V Canzian F Haugen A Polymorphisms of the interleukin-1 beta gene are associated with increased risk of non-small cell lung cancer Int J Cancer 2004 109 353 356 14961572
  41. [47]Hu Z Shao M Chen Y Allele 2 of the interleukin-1 receptor antagonist gene (IL1RN*2) is associated with a decreased risk of primary lung cancer Cancer Lett 2006 236 269 275 16019127
  42. [48]Lust JA Lacy MQ Zeldenrust SR Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component Mayo Clin Proc 2009 84 114 122 19181644 PMC2664581
  43. [49]Hong DS Hui D Bruera E MABp1, a first-in-class true human antibody targeting interleukin-1alpha in refractory cancers: an open-label, phase 1 dose-escalation and expansion study Lancet Oncol 2014 15 656 666 24746841
  44. [50]Ridker PM Everett BM Thuren T Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease N Engl J Med 2017 377 1119 1131 28845751
  45. [51]Ridker PM MacFadyen JG Thuren T Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial Lancet 2017 390 1833 1842 28855077

Cited by

Sorted by citations

Authors
Mantovani, A., Barajon, I., & Garlanda, C.
Affiliations
  • Humanitas University (IT)
  • Humanitas Clinical and Research Center Milan Italy
Corresponding author
Mantovani, Alberto
ORCID
Venue
Immunological Reviews
Publisher
Wiley
Published
2017-12-16
Volume
281
Issue
1
Pages
57-61
ISSN
  • 0105-2896 (ISSN-L)
  • 1600-065X
DOI
10.1111/imr.12614
PMC
PMC5922413
OpenAlex
W2774856823
Cited by
376
References
6
Citations by year
2026: 26 · 2025: 34 · 2024: 44 · 2023: 50 · 2022: 60 · 2021: 62 · 2020: 57 · 2019: 27 · 2018: 15 · 2017: 1
FWCI
2.87
Type
journal article
Language
en
Open access
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Immunological Reviews (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
Funders
  • Fondazione Cariplo (2015‐0564)
  • Ministero della Salute ((RF‐2011‐02348358 and RF‐2013‐02355470))
  • Ministero dell’Istruzione, dell’Università e della Ricerca ((PRIN 2015YYKPNN))
  • H2020 European Research Council (669415)
  • Associazione Italiana per la Ricerca sul Cancro ((AIRC IG‐19014 and AIRC 5x1000‐9962))
Topics
  • Health Sciences › Medicine › Oncology › Cytokine Signaling Pathways and Interactions
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
  • Life Sciences › Immunology and Microbiology › Immunology › IL-33, ST2, and ILC Pathways
Keywords
interleukin-1, IL-1 receptor family, interleukin-1 receptor antagonist, IL1R2, IL-1R8, IL-37, tumor microenvironment, inflammation in cancer, carcinogenesis, tumor progression, tumor angiogenesis, IL-17 signaling, myeloid-derived suppressor cells, macrophage recruitment, metastasis
MeSH terms
Myeloid-Derived Suppressor Cells, Animals, Humans, Immunotherapy, Interleukin-1, Neoplasm Metastasis, Neoplasms, Neovascularization, Pathologic, Signal Transduction, Receptors, Interleukin-1, Interleukin-17, Immunomodulation, Tumor Microenvironment, Carcinogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review